Certara, Inc. (NASDAQ:CERT) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Consensus "Hold": Thirteen analysts cover Certara with a consensus rating of Hold (1 sell, 6 hold, 5 buy, 1 strong buy) and an average 12‑month target of about $10.44.
• Recent results missed expectations: Certara reported $0.09 EPS versus a $0.11 consensus and $103.65M revenue roughly in line, and set FY‑2026 guidance of $0.440–0.480 EPS while sell‑side forecasts ~0.29 EPS for the current year.
• Stock profile: shares opened at $6.24 with a 12‑month range of $5.19–$14.39, a market cap around $957M, and institutional ownership of about 73.96%.

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have received a consensus recommendation of "Hold" from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.4444.

CERT has been the subject of several research analyst reports. Barclays reaffirmed an "equal weight" rating and set a $8.00 target price on shares of Certara in a research note on Friday, March 6th. TD Cowen reaffirmed a "buy" rating on shares of Certara in a research note on Thursday, February 26th. Leerink Partners reaffirmed an "outperform" rating and set a $10.00 target price on shares of Certara in a research note on Thursday, February 26th. Craig Hallum lowered shares of Certara from a "buy" rating to a "hold" rating and set a $10.00 target price for the company. in a research note on Friday, February 27th. Finally, KeyCorp lowered their target price on shares of Certara from $10.00 to $8.00 and set an "overweight" rating for the company in a research note on Monday, April 13th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. boosted its stake in Certara by 2,733.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company's stock worth $26,000 after buying an additional 2,870 shares during the period. First Horizon Corp purchased a new position in shares of Certara in the third quarter valued at approximately $30,000. Versant Capital Management Inc boosted its stake in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company's stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Finally, Global Retirement Partners LLC boosted its stake in shares of Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company's stock valued at $69,000 after purchasing an additional 1,749 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Price Performance

Certara stock opened at $6.24 on Tuesday. Certara has a 12-month low of $5.19 and a 12-month high of $14.39. The stock has a market cap of $956.72 million, a P/E ratio of -624.00 and a beta of 1.62. The company has a 50-day moving average price of $6.30 and a 200 day moving average price of $8.36. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.Certara's revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Sell-side analysts anticipate that Certara will post 0.29 earnings per share for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company's offerings are divided into software tools and consulting services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.